Literature DB >> 1526239

In vitro antimicrobial susceptibility of viridans streptococci isolated from blood cultures.

E Potgieter1, M Carmichael, H J Koornhof, L J Chalkley.   

Abstract

The susceptibility of 211 viridans streptococci isolated from blood cultures to eight antimicrobial agents was determined. All the isolates were susceptible to cefotaxime, ceftriaxone, imipenem and vancomycin. Thirty eight percent of the isolates were resistant to penicillin (MICs greater than or equal to 0.25 micrograms/ml). Tetracycline resistance was found in 41% of the isolates and in 7% of these strains tetracycline resistance was combined with erythromycin resistance. Five Streptococcus mitis isolates exhibited increased (MIC 64 micrograms/ml and 128 micrograms/ml) or high-level (MIC greater than or equal to 500 micrograms/ml) resistance to gentamicin, kanamycin and tobramycin. Four of these isolates were also resistant to penicillin (MICs 16-32 micrograms/m). In vitro synergy was not demonstrated for combinations of penicillin and gentamicin against three Streptococcus mitis isolates with gentamicin MICs of 1000, 128 and 64 micrograms/ml. Results of this study indicate the importance of monitoring antibiotic resistance trends in viridans streptococci particularly with respect to penicillin and aminoglycoside resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1526239     DOI: 10.1007/bf01960811

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

Review 1.  Functions and activities of the Area Committee on Microbiology of the National Committee for Clinical Laboratory Standards.

Authors:  J A Washington
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

2.  Combined resistance to erythromycin and tetracycline in streptococci.

Authors:  T G Winstanley; M H Wilcox; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1991-07       Impact factor: 5.790

3.  The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options.

Authors:  R C Moellering
Journal:  J Antimicrob Chemother       Date:  1991-07       Impact factor: 5.790

4.  Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986.

Authors:  K P Klugman; H J Koornhof
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

Review 5.  Molecular genetics of resistance to macrolides, lincosamides and streptogramin B (MLS) in streptococci.

Authors:  T Horaud; C Le Bouguenec; K Pepper
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

6.  Ribosomal resistance of clinical enterococcal to streptomycin isolates.

Authors:  G M Eliopoulos; B F Farber; B E Murray; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci.

Authors:  B F Farber; G M Eliopoulos; J I Ward; K Ruoff; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

8.  Differentiation of Streptococcus sanguis and S. mitior by whole-cell rhamnose content and possession of arginine dihydrolase.

Authors:  T Price; G L French; H Talsania; I Phillips
Journal:  J Med Microbiol       Date:  1986-05       Impact factor: 2.472

9.  Meningitis caused by multiply antibiotic-resistant viridans streptococci.

Authors:  J Goldfarb; G P Wormser; J H Glaser
Journal:  J Pediatr       Date:  1984-12       Impact factor: 4.406

10.  Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns.

Authors:  B F Farber; G M Eliopoulos; J I Ward; K L Ruoff; V Syriopoulou; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

  10 in total
  11 in total

1.  Species belonging to the "Streptococcus milleri" group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens.

Authors:  C Bantar; L Fernandez Canigia; S Relloso; A Lanza; H Bianchini; J Smayevsky
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

Review 2.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Enhanced activity of the combination of penicillin G and gentamicin against penicillin-resistant viridans group streptococci.

Authors:  E Cercenado; M D Díaz; C Sánchez-Carrillo; T Vicente; J C Bernaldo de Quirós
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

4.  Prospective study of Streptococcus milleri bacteremia.

Authors:  E Casariego; A Rodriguez; J C Corredoira; P Alonso; A Coira; M Bal; M J López; J Varela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

Review 5.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

6.  Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients.

Authors:  H Wisplinghoff; R R Reinert; O Cornely; H Seifert
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

7.  High incidence of erythromycin-resistant streptococci in Taiwan.

Authors:  J J Wu; K Y Lin; P R Hsueh; J W Liu; H I Pan; S M Sheu
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

8.  Chromosomally mediated high-level gentamicin resistance in Streptococcus mitis.

Authors:  A Kaufhold; E Potgieter
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

9.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Defining antibody targets in Streptococcus oralis infection.

Authors:  J P Burnie; W Brooks; M Donohoe; S Hodgetts; A al-Ghamdi; R C Matthews
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.